Lugano, Switzerland, April 11, 2016: Helsinn, the Swiss pharmaceutical Group focused on building quality cancer care, announces that it is supporting the NCCN Foundation® in the development of NCCN Guidelines for Patients® and a correspondent NCCN Quick Guide™, patient education materials on the management of nausea and vomiting through a sponsorship grant.

The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 27 of the nation’s leading cancer centers devoted to patient care, research and education, is dedicated to improving the quality, effectiveness and efficiency of cancer care so that patients can live better lives. The NCCN Foundation furthers this mission by delivering patient education resources and grants funding for young investigators at NCCN Member Institutions.

This patient education booklet focuses on nausea and vomiting, side effects that impact up to 80 percent of all cancer patients, according to the American Cancer Society[1],[2]. These symptoms are so feared that cancer patients sometimes refuse treatment in order to avoid them. Recent developments in medicine and cancer-supportive care have enabled significant advances in the management of these debilitating symptoms, and new drugs and therapies are now available which can help patients manage them better.

The booklet will join NCCN’s growing library of clinically accurate, accessible cancer education material for patients. It will provide guidance on a range of topics around the management of nausea and vomiting including symptom types and their associations with particular types of cancer treatment. Methods to manage these symptoms and support in addressing the physical and emotional challenges associated with them will also form a key component of the advice.

Once released, the booklets will be available on NCCN’s Patient and Caregiver Resources at guidelines to view and download at no cost.  If funding permits, free printed copies will be made available.  Readers can also obtain bound copies of the booklet on Amazon for a small fee. The booklets are utilized within the NCCN Member Institutions, at non-NCCN institutions, as well as collaborating cancer organizations across the US.

Riccardo Braglia, Helsinn Group Vice Chairman and CEO, said: “NCCN and NCCN Foundation provides an invaluable resource to people with cancer, their physicians and caregivers. Helsinn has for the past 40 years been committed to improving the everyday lives of patients, always guided by our core family values of respect, integrity and quality.

“As the range and effectiveness of cancer supportive care therapies and strategies improve, NCCN is helping those in need access critical information which can help them make decisions that will improve their quality of life. Helsinn is delighted to be able to help support this booklet.”



About Helsinn Group

Helsinn is a privately owned cancer-supportive care pharmaceutical group with an extensive portfolio of marketed products and a broad development pipeline. Since 1976, Helsinn has been improving the everyday lives of patients, guided by core family values of respect, integrity and quality, through a unique integrated licensing business model working with long-standing partners in pharmaceuticals, medical devices and nutritional supplement products. Helsinn is headquartered in Lugano, Switzerland, with operating subsidiaries in Ireland and the US, a representative office in China, as well as a product presence in about 90 countries globally.

In 2016, our 40th anniversary year, you can meet representatives from Helsinn at:

  • ASCO Annual Meeting (Chicago, USA, 3-7 June)
  • MASCC Annual Meeting (Adelaide, Australia, 23-25 June)
  • ChemOutsourcing Conference (Parsippany, New Jersey, 19-21 September)
  • CPhI Worldwide (Barcelona, Spain, 4-6 October)
  • ESMO Congress (Copenhagen, Denmark, 7-11 October)
  • BioEurope (Köln, Germany, 4-6 November)

For more information, please visit

For more information, please contact:

Helsinn Group

Paola Bonvicini

Head of Communication & Press Office

PH +41 91-985-21-21

[email protected]



<< Back